Navigation Links
Amgen To Host Post American Society of Hematology (ASH) Summary Webcast
Date:12/10/2013

THOUSAND OAKS, Calif., Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president of Global Commercial Operations at  Amgen, will participate in the call to discuss a brief summary of data presented at ASH. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis® (carfilzomib) across all lines of therapy to address unmet needs in multiple myeloma patients.

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/19/2014)... October 19, 2014 The Latin American ... market in Latin America with analysis and forecast of ... 2013, and is expected to reach $2,366.8 million by ... 2018. , Browse through the TOC of the Latin ... of the in-depth analysis provided. It also provides a ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... GAITHERSBURG, Md., Aug. 25 GenVec, Inc. (Nasdaq: ... 2 Small Business Innovation and Research (SBIR) grant from the National ... of Health (NIH) to support the development of GenVec,s vector production ... 2 0081205/DC50112LOGO ) , , ...
... WAYNE, Pa., Aug. 24 Encorium Group, Inc. (Nasdaq: ... (CRO) that provides design, development, and management capabilities for clinical ... pharmaceutical companies, today announced its financial results for the second ... As previously announced, on July 16, 2009 the Company sold ...
... , JACKSONVILLE, Fla., Aug. 24 In response ... to deploy social networking tools for their members or constituents, ... the Engageon Association Builder (EAB). The first launch was developed ... at www . lipid.org . ...
Cached Biology Technology:GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development 2Encorium Reports Second Quarter 2009 Financial Results 2Encorium Reports Second Quarter 2009 Financial Results 3Encorium Reports Second Quarter 2009 Financial Results 4Encorium Reports Second Quarter 2009 Financial Results 5Encorium Reports Second Quarter 2009 Financial Results 6Encorium Reports Second Quarter 2009 Financial Results 7Encorium Reports Second Quarter 2009 Financial Results 8Encorium Reports Second Quarter 2009 Financial Results 9Engageon Releases First Peer-to-Peer Medical Association Social Network 2
(Date:10/22/2014)... 2014  Leading identity analyst firm Acuity Market Intelligence ... world,s population will have a chip-based National eID card, ... . Asia , with its vast ... more than 60% of all National eID cards issued ... "The Global National eID Industry Report: 2014 ...
(Date:10/18/2014)... Berlin, 19th October 2014 Psychological stress and stress-related ... for aging-related diseases, but the molecular mechanisms ... mechanisms may contribute to the development of ... treatments for these devastating diseases. This work ... Neuropsychopharmacology congress in Berlin., Now an international ...
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... that has shown promise in skin disease and hemophilia might ... a new study by researchers at Stanford University School of ... in the Proceedings of the National Academy of Sciences the ... introduce a healthy copy of the gene dystrophin into mice ...
... the process that controls plant growth may help explain ... international team of scientists. , ,Researchers from Purdue ... the first time that proteins similar to multi-drug resistant ... cells, said Purdue plant cell biologist Angus Murphy. Because ...
... Although researchers over recent years have established a foothold ... by which it might contribute to aging and lifespan ... researchers studying p53 function in fruit flies show new ... a guardian against tumor formation, normal levels of p53 ...
Cached Biology News:Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 2Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 3Plant gene related to cancer treatment may foster new oncology drugs 2Plant gene related to cancer treatment may foster new oncology drugs 3New clues to the dark side of a key anti-tumor guardian 2
... S2 cells are used for heterologous protein ... (DES). The S2 cell line was derived ... hours old) Drosophila melanogaster embryos (1). ... room temperature without CO2 and is easily adapted ...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
... For our novel expression vectors, we in-troduced ... dual controls: (i) at tran-scriptional level at the ... replication level by amplifying the plasmid copy number, ... is that it retains practically all of the ...
... This CLS number is a new ... product number. If showing no availability yet, ... (C6421) or contact customer service for assistance. ... Comp Dim: surface area 21 cm ...
Biology Products: